Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 275 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Reflux Acid Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

NCT00992589
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
1 Month to 11 Months
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Columbiana, Alabama • Dothan, Alabama + 40 more
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Jul 22, 2026, 4:57 PM EDT
No Longer Available No phase listed Expanded access

Treatment Use of Domperidone for Gastroparesis

NCT02227927
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, GERD, Gastroparesis
Interventions
Domperidone
Drug
Lead sponsor
Scott Gabbard, MD
Other
Eligibility
18 Years and older
U.S. locations
2
States / cities
Weston, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Jul 22, 2026, 4:57 PM EDT
Completed No phase listed Observational Results available

Complications, Outcomes and Revisions Following Hiatal Hernia Repair With MIROMESH

NCT03735862
View directory record Official record
Conditions
Hiatal Hernia With Gastroesophageal Reflux Disease, Gastroesophageal Reflux, GERD
Interventions
Hepatic derived surgical matrix
Biological
Lead sponsor
Miromatrix Medical Inc.
Industry
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lorton, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)

NCT00149851
View directory record Official record
Conditions
Symptomatic Gastroespohageal Reflux Disease
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
832 participants
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Not applicable Interventional Results available

Endoscopic Implantation of Enteryx for the Treatment of GERD

NCT00346905
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Enteryx
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Jul 22, 2026, 4:57 PM EDT
Completed No phase listed Observational

Gastric Bypass After Previous Anti-reflux Surgery

NCT01041105
View directory record Official record
Conditions
Clinically Severe Obesity, Gastroesophageal Reflux Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Dec 31, 2009 · Synced Jul 22, 2026, 4:57 PM EDT
Completed No phase listed Observational

Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?

NCT01373125
View directory record Official record
Conditions
Barrett's Esophagus, Intestinal Metaplasia, Gastroesophageal Reflux Disease (GERD)
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease

NCT04799158
View directory record Official record
Conditions
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Anniston, Alabama • Athens, Alabama • Huntsville, Alabama + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Jul 22, 2026, 4:57 PM EDT
Completed No phase listed Observational

A Post-Approval Study of the LINX® Reflux Management System

NCT01940185
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
LINX device
Device
Lead sponsor
Torax Medical Incorporated
Industry
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • Englewood, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jul 22, 2026, 4:57 PM EDT
Terminated Not applicable Interventional Results available

COPD Patients Diagnosed With GERD,COPD Exacerbations After Treatment With High Dose PPI

NCT00523367
View directory record Official record
Conditions
Gastroesophageal Reflux, Chronic Obstructive Pulmonary Disease
Interventions
24 hour pH testing
Procedure
Lead sponsor
University of Florida
Other
Eligibility
40 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

NCT00321984
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
153
States / cities
Alabaster, Alabama • Birmingham, Alabama • Hueytown, Alabama + 150 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Jul 22, 2026, 4:57 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Fundoplication in Laparoscopic PEH Repair Based on FLIP

NCT05807763
View directory record Official record
Conditions
Paraesophageal Hernia
Interventions
Laparoscopic paraesophageal hernia repair without fundoplication
Procedure
Lead sponsor
The Foundation for Surgical Innovation and Education
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
2
States / cities
Evanston, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Not applicable Interventional

Tolerability Study of a Novel Microbiome Therapeutic in Subjects With Gastroesophageal Reflux Disease

NCT04491734
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
maltosyl-isomalto-oligosaccharides (MIMO)
Dietary Supplement
Lead sponsor
ISOThrive Inc.
Industry
Eligibility
25 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2021 · Synced Jul 22, 2026, 4:57 PM EDT
Recruiting Not applicable Interventional

External UES Band (Shaker Pressure Band) and GERD

NCT05697393
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Shaker Pressure Band
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Pantoprazole in Children With GERD

NCT00141817
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole for approximately 9 weeks.
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
1 Year to 11 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
23
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2011 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Not applicable Interventional

Comparison of Laparoscopic Hill and Laparoscopic Nissen Anti-Reflux Procedures

NCT01260935
View directory record Official record
Conditions
Gastroesophageal Reflux, Esophageal Reflux, Gastroesophageal Reflux Disease, GERD
Interventions
Laparoscopic Hill Repair, Laparoscopic Nissen Repair
Procedure
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 17, 2012 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Phase 4 Interventional Results available

Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US

NCT00660660
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
45
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2015 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Phase 1 Interventional

Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux

NCT00864396
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Prevacid
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Jul 22, 2026, 4:57 PM EDT
Withdrawn Phase 4 Interventional

Dexilant Treatment in Gastrointestinal Reflux Disease (GERD Related Non Cardiac Chest Pain

NCT01637571
View directory record Official record
Conditions
Chest Pain, Gastrointestinal Reflux Disease
Interventions
Dexilant, Dexilant Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Pumosetrag in Patients With Gastroesophageal Reflux Disease (GERD)

NCT01161602
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Pumosetrag, Placebo
Drug · Other
Lead sponsor
Edusa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2011
U.S. locations
5
States / cities
Scottsdale, Arizona • Anaheim, California • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Jul 22, 2026, 4:57 PM EDT
Not listed Phase 1Phase 2 Interventional

Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2

NCT04846010
View directory record Official record
Conditions
Sequelae of; Infection, Post Infection Glomerulonephritis, Post-Infectious Peripheral Neuralgia, Post-Infectious Disorder (Disorder), Post-Infectious Arthritis, Post-Infectious Polyneuritis, Post-Infectious Parkinsonism, Post-Infectious Hypothyroidism, Post Infectious Osteoarthritis, Anxiety Disorders, Depression, Depression, Anxiety, Depression, Bipolar, Insomnia, GERD, Gastro Esophageal Reflux, Hepatitis, Glomerulonephritis
Interventions
PurWet, FurFat, PurApo, PurPhl, PurClo, PurInf, Smoliv
Combination Product
Lead sponsor
All Natural Medicine Clinic, LLC
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Results available

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT01472939
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
SSP-002358 (0.1 mg) + PPI, SSP-002358 (0.5 mg) + PPI, SSP-002358 (2.0 mg) + PPI, Placebo + PPI
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
62
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Jul 22, 2026, 4:57 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy.

NCT00237068
View directory record Official record
Conditions
Asthma
Interventions
Lansoprazole; Solutab
Drug
Lead sponsor
Emory University
Other
Eligibility
4 Years to 11 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2011 · Synced Jul 22, 2026, 4:57 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Evaluation of Esomeprazole in Treating Gastro-esophageal Reflux Disease (GERD) in Head and Neck Cancer Patients Exposed to Radiation Therapy

NCT00222079
View directory record Official record
Conditions
Gastro-esophageal Reflux
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
Douglas Trask
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Jul 22, 2026, 4:57 PM EDT